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Background: The aim of this study was to determine the impact of COVID-19 pandemic on the total testing
process using six sigma metrics based on a comparison of pre and during pandemic periods.
Material & methods: The study duration was over 12 months, 6 months before and 6 months after the COVID-19
onset in Pakistan in March 2020 after the recognition of the first case, using quality indicators (QIs). QIs were
chosen from a model of QIs recommended by the CAP. Analysis was performed using Six Sigma calculators and
QIs were expressed in percentage (%) and Sigma value were computed. Three levels of performance quality i.e.
25th, 50th, and 75th percentile were derived, being best, common and worst performance respectively. Betweengroup differences were tested using the Mann-Whitney’s U test.
Results: The median defect percentages of these QIs ranged from 0% to 0.27% for the pre-pandemic period and
0% to 0.13% for the during pandemic period. Meanwhile, sigma values of the majority of the QIs were all above
4.0σ during the pre and the pandemic times. For the pre-analytical phase, sigma scores declined for 1 QI,
improved for 3 QIs and remained same for 2. In the post analytical phase, no change in sigma metrics was noted
for critical values notification. Considerable increase in defect percentage of inappropriate turnaround times was
noted.
Conclusion: The emergency preparedness proved to be fruitful as depicted by exceptional performance on the
sigma metrics for most Qis both prior to and during the pandemic. The pre-analytical and the post analytical
phases, being the most error sensitive requires strict vigilance.

1. Introduction
The Corona virus disease 2019 (COVID-19) pandemic affected
almost every nation across the globe, impacting more than 20 million
lives alongside services and economic productivity [1]. The pandemic
triggered an unexpected global emergency which has had huge impact
on many organizations including health structure, health care pro
fessionals and clinical laboratories [2]. The part played by laboratory
medicine during a pandemic has been widely recognized [3]. A
comprehensive summary of previous researches strengthens the fact that
the diagnosis of COVID-19 would not have been possible without the
laboratory services, either by detecting the pathogen through reverse
transcriptase-polymerase chain reaction (RT-PCR), or quantifying anti
body response via immunological based techniques [4]. Hence,

laboratories have a crucial part to play during an infectious outspread
from the time of diagnosis till surveillance.
While the pandemic has highlighted the significance of laboratory
medicine in healthcare setups, laboratory testing is altogether an intri
cate process [5]. Each of the various steps involved total testing process
can result in errors and they can have a huge impact on patient prognosis
[6]. In laboratory practice, total testing process is divided into three
crucial steps: pre-analytical, analytical and post-analytical [7]. Quality
indicators are considered as the fundamental tools of maintaining
quality in laboratory systems that can be gauged to assess each step of
total testing process. The utilization of quality indicators in clinical
laboratory allows determining error incidence and diminishing or
arresting patient safety errors [8].
This COVID-19 pandemic has clearly exhausted the laboratories
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Table 1
QIs representing pre and post analytical phase from pre- and during pandemic periods.

PreAnalytical
Phase

PostAnalytical
Phase

Quality Indicators

Period

Defect percentage (%)

Sigma values

Percentage of number of hemolyzed samples/total number of samples

Pre-pandemic
During
pandemic

Percentage of number of QNS samples/total number of samples

25th

50th

75th

25th

50th

75th

0.05
0.05

0.05
0.06

0.06
0.06

4.8
4.7

4.7
4.7

4.7
4.7

0.16

Pre-pandemic
During
pandemic

0.01
0.01

0.02
0.01

0.02
0.02

5
5

5
4.9

4.9
5.1

1.00

Percentage of number of empty container/total number of samples

Pre-pandemic
During
pandemic

0
0

0
0

0
0

6
6

6
6

6
6

0.93

Percentage of number of bad barcode samples/total number of
samples

Pre-pandemic
During
pandemic

0
0.005

0
0.03

0.01
0.04

5
4.6

4.9
4.7

4.4
4.5

0.81

Percentage of number of without barcode sample/total number of
samples

Pre-pandemic
During
pandemic

0.16
0.07

0.23
0.1

0.27
0.13

4.5
4.7

4.4
4.6

4.3
4.4

0.87

Percentage of number of leaking container/total number of samples

Pre-pandemic
During
pandemic
Pre-pandemic
During
pandemic

0
0

0
0

0
0

6
6

6
6

6
6

0.93

0
0

0
0

0
0

6
6

6
6

6
6

0.93

Pre-pandemic
During
pandemic

0.003
0.006

0.003
0.008

0.004
0.009

4.4
4.4

4.5
4.4

4.3
4.6

0.37

Percentage of number of critical results informed within time/total
number of samples
Percentage of number of STAT samples/total number of samples

pvalue

resources with obstacles such as shortage of staff, conveyance issues,
short supply of personal protective equipment (PPE), delayed shipments
of necessities, and particularly, fear and anxiety amongst healthcare
workers. The preparations to tackle such crises are never mentioned in
the books of laboratories especially for resource constrained setups in
developing world.
During the ongoing pandemic, the healthcare professionals were
made to follow additional caution and wear recommended PPE.
Accreditation and regulatory bodies are increasingly emphasizing lab
oratories to go beyond analytical quality and focus on the pre- and postanalytical phases, where most errors arise that can influence clinical
care. Furthermore, the specimen collection and transport logistics were
also considerably unalike from the pre-pandemic times [7,8]. The
impact of these changed protocols for specimen collection, packaging
and transport on the total testing process is not widely established. The
purpose of this study was to determine the impact of COVID-19
pandemic on the pre and post analytical testing process using six
sigma metrics based on a comparison of pre and pandemic periods.

was retrospectively retrieved from the electronic laboratory information
management system. At our center, the preanalytical, analytical, and
postanalytical processes are regularly monitored and recorded using QIs
and presented in monthly departmental quality management committee
meeting for appropriate actions if necessary. Quality indicators were
chosen from a model of QIs recommended by the CAP [9]. QIs were
categorized in accordance with the main TTP phases as shown in
Table 1.
Analysis was performed using Six Sigma calculators and QIs were
expressed in percentage (%) and sigma value were computed [10].
Three levels of performance quality i.e., 25th, 50th, and 75th percentile
was derived, being best, common and worst performance respectively as
described previously by Sciacovelli L et al. [11]. Between-group differ
ences were tested using the Mann-Whitney’s U test taking a p-value of
<0.05 as statistically significant difference. The Statistical Package for
Social Sciences (SPSS) software program (v.22; IBM, Armonk, NY) and a
P < 0.05 was considered as statistically significant for all analyses. This
work has been reported in line with the STROCSS criteria [12].

2. Material & Methods

3. Results

This retrospective observational study was conducted at the Section
of Clinical Chemistry, Department of Pathology and Laboratory Medi
cine at Aga Khan University Hospital (AKUH), Karachi, Pakistan. The
clinical laboratory is the largest reference laboratory catering a country
wide population of 240 million with its growing network of more than
280 phlebotomy stations and stat laboratories spread across Pakistan.
The laboratory operates to highest standards of quality and was the first
to be accredited by Joint Commission International Accreditation (JCIA)
and the only lab with College of American Pathologist (CAP) accredi
tation in Pakistan.
This study was done to evaluate the repercussions of the pandemic
on the quality of the test process. The study duration was 12 months, 6
months before and 6 months following the COVID-19 onset in Pakistan
in March 2020 after the recognition of the first case, using Q6 Is. Data

A total of 2,528,589 specimens were screened of which 999,437
(40%) were received during the pandemic phase. A total of 30,926
critical results were informed out of which 12,118 (39%) were during
the pandemic phase. Moreover, 214,884 stat results were processed of
which 83,065 (39%) were during the pandemic period. The error rates
for all QIs were regularly monitored, against established benchmarks,
adopted from the Q-Probes and Q-Tracks studies from CAP. A review of
the records revealed that all the Qis were well within the respective
benchmarks [13].
Defect percentages and sigma values related to pre-analytical,
analytical and post-analytical phase are depicted in Table 1. The me
dian defect percentages of these QIs ranged from 0% (leaking con
tainers) to 0.27% (manual labeling, without barcode) for the prepandemic period and 0% (leaking containers) to 0.13% (without
2
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Fig. 1. Sigma trend of quality indicators.

barcode samples) for the during pandemic period. The QIs were moni
tored through rigorous and vigilant practices at the receiving and pro
cessing bench housed by a team of technologists led by a charge
technologist. As correct patient identification and correct specimen la
beling are recognized cardinal safety goals by CAP, without barcode
samples with manual entries were visually scanned and segregated. The
entries were re-verified from the test requisition slips and barcodes
generated and applied for optimal further processing and analysis.
For the 1 QI (bad barcode samples) defect percentages increased with
a decrement in sigma values during the pandemic compared to the prepandemic phase. On the contrary, sigma metrics improved, and defect
percentages went down for 2 QIs (number of insufficient quantity (QNS)
samples, number of without barcode samples). Whereas sigma values for
3 QIs (hemolyzed samples, leaking containers, empty containers) were
almost the same before and during the pandemic.
Amongst the 2 QIs related to the post analytical phase, no change in
sigma metrics was noted for critical values notification. While there was
a considerable increase in defect percentage of inappropriate turn
around times with lower sigma scores compared to the pre pandemic era
as depicted in Table 1. However, as the difference between the pandemic
and pre pandemic era was not significant, the p-values calculated were
not statistically significant. Meanwhile, sigma values of the majority of
the QIs were all above 4.0σ before and after the onset of the pandemic as
depicted by the graphical trends in Fig. 1.

that prevented any major decline in the sigma scores in this vulnerable
pandemic phase.
In the post analytical phase, the critical result reporting maintained
the sigma benchmark of the pre-pandemic era. However, few stat delays
were encountered during the pandemic phase. Our findings are in
contrast with Eren F et al. and colleagues who have reported high per
centage of critical reporting delays during the pandemic at a clinical
laboratory in Ankara [18]. The few instances of stat delays were linked
with delayed specimen transport from clinical care areas, which may be
related to staff shortages.
There were certain limitations of our study, notably more than 15 QIs
could be used to evaluate the testing processes, however the most sig
nificant ones that can impact lab performances were examined in this
study. Moreover, the performance of external quality assessments and
proficiency testing was not assessed on the sigma metrics, because of the
difference in time intervals of different surveys which may influence
sigma calculations.
5. Conclusion
Identification of lab errors, rectification and vigilance serve as pillars
of total quality management. The emergency preparedness and strate
gies adopted amidst the crisis situation proved to be fruitful as depicted
by exceptional performance on the sigma metrics for most QIs in the
high-volume reference laboratory in Pakistan. The pre-analytical and
the post-analytical phases, being the most error sensitive requires strict
vigilance to maintain good quality assurance in a clinical laboratory.

4. Discussion
This study is the first to assess the impact of the pandemic on the
testing processes at a high-volume clinical chemistry laboratory in
Pakistan, a lower middle-income country hardest hit by the pandemic.
The sudden rise in cases, increasing demands of prognostic biomarkers
including ferritin, lactate dehydrogenase, procalcitonin, interleukin-6
and c-reactive protein and different coping strategies adopted, led to
enhanced workload and pressure on laboratory staff, making them
prone to errors [14,15]. As anticipated, a mixed trend was noted for the
QIs on comparison between the pre and during pandemic phases, with
improvements in some areas to regression in others.
From a laboratorian’s perspective, the pre-analytical errors account
for up to 70% of all mistakes made in laboratory diagnostics [16]. It is
this phase that can highly influence the test results in turn impacting
medical decisions. However, in this study only one QI belonging to the
pre-analytical phase showed a decline whereas the sigma scores for the
others QIs either remained unchanged or showed an improving trend.
Our results are in contrast to Tapasyapreeti M et al., who have reported
that preanalytical errors and resultant blood specimen rejection rate at a
clinical laboratory in India have significantly increased due to changed
logistics [17]. This comparison substantiates the impact of contingency
measures taken by our laboratory to facilitate logistics and staff short
ages managed appropriately even during the strict lock down period,
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